Prosecution Insights
Last updated: April 19, 2026

Examiner: MORGAN, BAILEY MICHELLE

Tech Center 1600 • Art Units: 1645

This examiner grants 58% of resolved cases

Performance Statistics

57.9%
Allow Rate
-2.1% vs TC avg
49
Total Applications
+53.3%
Interview Lift
919
Avg Prosecution Days
Based on 19 resolved cases, 2023–2026

Rejection Statute Breakdown

5.6%
§101 Eligibility
21.1%
§102 Novelty
24.8%
§103 Obviousness
31.6%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18263277 LIPID NANOPARTICLE ADJUVANT COMPOSITION FOR PNEUMOCOCCAL CONJUGATE VACCINES Non-Final OA Merck Sharp & Dohme LLC
18014004 MODIFIED YEAST HOST CELLS USEFUL FOR PRODUCING ISOPRENOL Final Rejection The Regents of the University of California
18210416 GENETIC PLATFORM TO INVESTIGATE THE FUNCTIONS OF BACTERIAL DRUG EFFLUX PUMPS Non-Final OA University of Guelph
17905592 METABOLIC ENGINEERING FOR PRODUCTION OF LIPOIC ACID Non-Final OA National University of Singapore
17637057 APPLICATION OF PSEUDOMONAS AERUGINOSA VACCINE IN TREATING INFECTION ASSOCIATED WITH BURN OR SCALD INJURY Final Rejection Sichuan University
17637028 APPLICATION OF PSEUDOMONAS AERUGINOSA VACCINE IN RESPIRATORY DISEASE Non-Final OA Sichuan University
18034239 IMMUNOGENIC COMPOSITIONS FOR USE IN PNEUMOCOCCAL VACCINES Non-Final OA Pfizer Inc.
17794744 INCREASED ETHANOL PRODUCTION BY OVEREXPRESSION OF JID1 IN YEAST Non-Final OA DANISCO US INC.
18268032 BURKHOLDERIA VACCINES AND THERAPEUTICS Non-Final OA University of Hawaii
17935466 BACILLUS SUBTILIS STRAIN, RECOMBINANT BACILLUS SUBTILIS STRAIN AND USE THEREOF Non-Final OA Jiangnan University
18697281 PROBIOTIC ENHANCERS AND USES THEREOF Non-Final OA Blis Technologies Limited
17854377 PNEUMOCOCCAL CAPSULAR SACCHARIDE CONJUGATE VACCINE Final Rejection GLAXOSMITHKLINE BIOLOGICALS SA
17763354 IMMUNOGENIC COMPOSITIONS Final Rejection GLAXOSMITHKLINE BIOLOGICALS SA
18257420 CONJUGATED T-2 TOXIN TO PROTECT AGAINST MYCOTOXICOSIS Non-Final OA INTERVET INC.
18162137 ANTIPHOSPHOLIPID ANTIBODIES FOR THE DIAGNOSIS OF LYME DISEASE Non-Final OA Trustees of Tufts College
17904155 PREVENTION AND TREATMENT OF INFECTIONS INCLUDING THOSE CAUSED BY CORONAVIRUS Final Rejection IMMODULON THERAPEUTICS LIMITED
18246564 STANDARDISED CYANOBACTERIAL STRAIN ENGINEERING Non-Final OA BONDI BIO PTY LTD
18245884 ANTIBODIES AGAINST STREPTOCOCCAL M PROTEIN Final Rejection Aventera Antibodies AB
18017934 THERAPEUTIC AGENT OR DIAGNOSTIC AGENT FOR CANCER Final Rejection JAPAN ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY
17998693 FUSION PROTEIN WITH IMMUNOENHANCING ACTIVITY Non-Final OA Transmed Gothenburg AB
17917010 IMPROVEMENTS IN VACCINE FORMULATIONS FOR MEDICAL USE Final Rejection Valneva Austria GmbH
17754427 NOVEL SKIN CARE COMPOSITION Non-Final OA S-BIOMEDIC

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month